NCT06219915View on ClinicalTrials.gov

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 15, 2024

Primary Completion Date

May 30, 2024

Study Completion Date

May 30, 2024

Conditions
Parkinsonian Signs in Older Persons
Interventions
DRUG

Carbidopa 25 mg

Participants will take one 25mg Carbidopa tablet 3 times a day for 10 days.

DRUG

Carbidopa-Levodopa 25/100 mg

Participants will take one 25/100mg carbidopa-levodopa tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.

DRUG

Placebo 1

Participants will take one 25mg placebo tablet 3 times a day for 10 days.

DRUG

Placebo 2

Participants will take one 100mg placebo tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.

Trial Locations (2)

48105

Domino's Farms, Ann Arbor

48109

University Hospital, Ann Arbor

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

University of Michigan

OTHER

NCT06219915 - Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm | Biotech Hunter | Biotech Hunter